News and Trends 1 Apr 2021 Have European Investors Missed the Exosome ‘Gold Rush’? When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled that investors are taking exosome therapies seriously. But a lack of European investors in the exosome field raises the very real possibility that the best opportunities have already passed, along with the chance to build an exosome ecosystem to rival […] April 1, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jun 2020 Update: Hyloris Raises €62M IPO to Create More Drug Delivery Options Update (29/06/2020): Hyloris Pharmaceuticals’ Euronext IPO — one of only a handful of biotech and pharma IPOs on European soil in the last 18 months — has hit the midpoint of its expected pricing range with a value of €61.8M. The shares were priced at €10.75 each, which was comfortably between the minimum target of […] June 29, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jun 2020 Evox and Lilly Partner to Develop Neuro RNA Drugs in Deal Worth €1.1B British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US big pharma Eli Lilly to develop RNA drugs that are delivered in exosomes to the brain to treat neurological diseases. As part of the deal, Evox will get €17.6M upfront to fund research for the next three years and Lilly […] June 11, 2020 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 14 Jun 2019 This Biotech Reduces Drug Side Effects Using Silica Gel Implants DelSiTech is a Finnish company developing injectable silica gel implants that release drugs slowly over time, causing fewer side effects and helping patients stick to their treatment regimen. Mission: To develop silica gels that slowly release drugs over time to treat conditions including HIV, hepatitis B, retinal disease and cancer. One big problem in chronic […] June 14, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Infographics 28 Nov 2018 Infographic: The Next Big Thing in Biological Drug Delivery By the year 2022, half of the top 100 drug sales will be biologics. And with 2,700 biologics currently in development, the market will soon be booming. But there is a hitch: Most biological drugs are administered parenterally. And though this is better than nothing, it does coincide with high treatment costs and stress for […] November 28, 2018 - 1 minutemin - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 3 Sep 2018 Oxford Biotech Raises €40M to Deliver Drugs to Hard-to-Reach Targets Evox Therapeutics has raised £35.5M (€39.4M) in a Series B fundraising that has been backed, among others, by the venture arm of Google’s parent company. A spin-out from the University of Oxford and the Karolinska Institute, Evox Therapeutics has raised a large round that will fund the development of its drug delivery technology to […] September 3, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 23 Feb 2018 Novo Nordisk Gets Close to Launching the First Oral GLP-1 Drug for Diabetes Novo Nordisk has positive Phase III trial results for its oral version of semaglutide, a GLP-1 based treatment for type II diabetes. This could be the first oral GLP-1 treatment on the market, making it easier for patients to take the drug. After obtaining approval for an injected version, Novo Nordisk is now getting ready […] February 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner Santa Claus is not the only busy one in the weeks leading up to Christmas this year, with Boehringer Ingelheim signing collaborations with Autifony and Evox Therapeutics. In the last couple of days, Boehringer Ingelheim has agreed to collaborate with two exciting British biotechs. On Monday, a deal worth up to €627.5M was agreed with CNS disorders specialist, […] December 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2016 Meet the French CEO who wants to Break Barriers to Drug Delivery The objective of the French biotechnology company, Vect-Horus, is to leverage its technology, VECTrans, to facilitate the delivery of drugs into the brain and other organs. For this innovation, the company recently received the Frost & Sullivan 2016 Leadership award, which independently recognizes companies for demonstrating excellence in developing innovative technologies and practices within an industry. […] October 10, 2016 - 5 minutesmins - By Marie Godar Share WhatsApp Twitter Linkedin Email